US EditionApotex, Grünenthal Sign Deal for Nebido Canadian Distribution
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism.The post Apotex and Grünenthal sign deal for Nebido Canadian distribution appeared first on Hospital Management.
pharmaceutical-technology.comPharmaceutical Business reviewApotex, Grünenthal sign deal for Nebido Canadian distribution
Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism.
Apotex Inc. Licenses Exclusive Cdn. Rights To New Injectable Drug
TORONTO and AACHEN — Apotex Inc. and Grünenthal, involved in pain management and related diseases, announced that they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), an injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency). Under the agreement, Searchlight Pharma, Apotex’s branded medicine division, will pursue marketing…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
